Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

Karyopharm Therapeutics (KPTI) closed the last trading session at $5.32, gaining 7.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 33.07 indicates a 521.6% upside potential.The average comprises seven short-term price targets ranging from a low of $8 to a high of$ 67.47, with a standard deviation of $23.37. While the lowest estimate indicates an increase of 50.4% from the curre ...